Sarepta Therapeutics Inc (SRPT.OQ)
23 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|54||2017||President, Chief Executive Officer|
|52||2017||Executive Vice President, Chief Financial Officer and Chief Business Officer|
|45||2012||Senior Vice President, General Counsel, Corporate Secretary|
|46||2016||Senior Vice President, Global Commercial Development|
|57||2016||Senior Vice President - Regulatory Affairs and Quality|
- Sarepta Therapeutics beats bid to revive shareholder class action
- BRIEF-Sarepta Therapeutics Announces Plan To Submit A New Drug Application For Accelerated Approval Of Golodirsen
- BRIEF-Sarepta Therapeutics Reports Q4 Non-GAAP Loss Per Share $0.28
- BRIEF-Capital Ventures International Reports 5.4 Pct Passive Stake In Sarepta Therapeutics
- Sarepta Therapeutics investors seek revival of fraud lawsuit